Suppression of plasma androgens by spironolactone in castrated men with carcinoma of the prostate.
Spironolactone, an inhibitor of androgen synthesis, has been administered to castrated men with metastatic carcinoma of the prostate. Plasma levels of testosterone, androstenedione and dehydroepiandrosterone were significantly decreased. These data indicate that spironolactone suppresses adrenal androgen production and suggest that it may be of benefit in the treatment of orchiectomized patients with advanced carcinoma of the prostate.
D000368:Aged; D000728:Androgens / Q000097:blood*; D000735:Androstenedione / Q000097:blood; D002369:Castration; D003687:Dehydroepiandrosterone / Q000097:blood; D003864:Depression, Chemical; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011471:Prostatic Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000473:pathology; D013148:Spironolactone / Q000494:pharmacology* / Q000627:therapeutic use; D013739:Testosterone / Q000097:blood
D000728:Androgens; D013148:Spironolactone; D013739:Testosterone; D000735:Androstenedione; D003687:Dehydroepiandrosterone